Our study illustrated that NHE1 expression is of significance to the pathogenesis of depression and characterised its regulatory signalling through ROCK2 inhibition, which provided evidence that the ROCK2/NHE1/calpain1 signalling pathway could be considered a potential target in the treatment of depression. Here, SLC9A1 is linked to depressive symptom measurement.